Neoadjuvant Therapy: What are the Lessons so far?

This article explains how diagnosis of a pathologic complete response (pCR) can avoid an unfavorable prognosis in patients with high-risk breast cancer; how the surrogacy of pCR for long-term survival remains questionable; how translational biomarker studies have not been helpful in identifying patients with a high chance of treatment benefit; assessment of the prognosis of patients without a pCR for identifying patients at high risk and which clinical trials will be available for these patients in the near future; and which patients might require less locoregional treatment.
PMID: 23915744 [PubMed - in process]

Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: von Minckwitz G Tags: Hematol Oncol Clin North Am Source Type: research